drugset
drugset / Trial / NCT00957372

Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy

NCT00957372 ↗

Phase 3 Completed 253 enrolled Bial - Portela C S.A.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective was to evaluate the efficacy of eslicarbazepine acetate (ESL) administered once daily at 1200 mg or 800 mg, compared with placebo as adjunctive therapy in patients with refractory partial epilepsy over a 12-week maintenance period.

Timeline

Start
2004-12
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Eslicarbazepine acetate Unknown 400 mg Oral
Subject Eslicarbazepine acetate Unknown 800 mg Oral
Subject Eslicarbazepine acetate Unknown 1200 mg Oral

Indications

focal epilepsy